Archives

img-01

China Squeezes Kickbacks in its Pharma Sector

While bribery has been significantly reduced in China’s medical market over the last five years, it still exists. For example, there have been significant reductions of payments to NMPA officials for drug approvals. However, in other areas of the Chinese medical system,... Read More

img-01

Asia’s CDx Market Poised for Growth

According to a recent market research report by Triton Market Research, Asia’s CDX market was valued at $1.4 billion in 2022 and is likely to grow to $3.85 billion by 2030 with a CAGR of 13%. While CDX growth has already accelerated... Read More

img-01

China Drug Registration

China is the second-largest drug market in the world. Registering drugs in China is more accessible today than ever. That does not mean it is easy or straightforward. Before attempting to do so, international drug companies should research the prevalence of the... Read More

img-01

China GMP Requirements and Audits for Drugs

Contact us today for a free consultation with a China regulatory affairs consultant to discuss your specific needs. To register a drug in China, the drug factory must meet China’s GMP standards. China initiated GMP requirements for drugs in 1988 but has revised... Read More

img-01

China GMP Requirements and Audits for Medical Devices

Contact us today for a free consultation with a China regulatory affairs consultant to discuss your specific needs. China GMP requirements are important for medical device registration in China. Key areas for China GMP requirements cover device manufacturing, product labeling, R&D design, warehousing,... Read More

img-01

China Updates Device Classification System

Device classification in China can sometimes be a tricky issue. If the classification is unclear, device companies can submit an online application to determine the classification. After the online submission, the applicant needs to submit hard copy documents and gain acceptance and... Read More

img-01

China Drug Patent Linkage Update

In 2021, China’s Patent Linkage regulation went into effect, and both the Chinese National IP Administration (CNIPA) and Beijing IP Court have the responsibility for determining patent linkage. To date, the Beijing IP court has reviewed over 12 patent linkage cases, and... Read More

img-01

China Strives to Improve Drug Safety

Recently, China’s NMPA has started to implement more programs for drug safety. Drug supervision has increased, and the number of crackdowns has jumped dramatically. Last year, there were about 160,000 regulatory investigations of false drug claims, inoperative medical devices, and other problematic... Read More